Overview

Candin for the Treatment of Common Warts

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: - does treatment with Candin result in better clearance of warts than placebo - how many injections are required to result in wart clearance Participants will - have one wart selected for injection every two weeks until clearance - return 12 weeks after wart clearance for assessment of durability of response
Phase:
Phase 3
Details
Lead Sponsor:
Nielsen BioSciences, Inc.